Department of Pharmacology, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, India.
Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, India.
Expert Rev Anti Infect Ther. 2021 Sep;19(9):1083-1092. doi: 10.1080/14787210.2021.1893692. Epub 2021 Mar 5.
: The novel coronavirus has caused significant mortality worldwide and is primarily associated with severe acute respiratory distress syndrome (ARDS). Apart from ARDS, clinical reports have shown noticeable cardiovascular complications among the patients of COVID-19. Infection from virus, stimulation of cytokine storm, altered immune response, and damage to myocardial tissue are some of the proposed mechanisms of cardiovascular complications in COVID-19.: Based on the clinical reports of CVDs among COVID-19 patients, we have discussed the molecular mechanisms involved in cardiovascular pathogenesis, its prevalence, and association with COVID-19, and various available therapeutic modality for the treatment.: Seeing the cardiovascular complications in COVID-19 patients and its association with the existing drug, risk-benefit ratio of treatment paradigm, as well as the level of cardiac injury biomarkers must be monitored regularly. Additionally, a well-designed clinical trial should be conducted where head to head comparison can be made with anti-COVID-19 drugs and cardioprotective anti-inflammatory drugs. Nevertheless, vaccines are the best-suited approach, but until then, sanitization, social distancing, and active lifestyle are the best ways to beat this global pandemic situation.
新型冠状病毒在全球范围内造成了大量死亡，主要与严重急性呼吸窘迫综合征（ARDS）有关。除了 ARDS，临床报告显示 COVID-19 患者中存在明显的心血管并发症。病毒感染、细胞因子风暴的刺激、免疫反应的改变以及心肌组织的损伤是 COVID-19 中心血管并发症的一些拟议机制。
基于 COVID-19 患者中 CVD 的临床报告，我们讨论了心血管发病机制中涉及的分子机制、其患病率以及与 COVID-19 的关联，以及治疗的各种可用治疗方法。
鉴于 COVID-19 患者的心血管并发症及其与现有药物的关联、治疗方案的风险效益比以及心脏损伤生物标志物的水平，必须定期进行监测。此外，应进行精心设计的临床试验，以便可以对 COVID-19 药物和心脏保护性抗炎药物进行头对头比较。然而，疫苗是最合适的方法，但在那之前，消毒、保持社交距离和积极的生活方式是应对这种全球大流行情况的最佳方法。
